基于EGFR、KRAS、ALK分型非小细胞肺癌临床病理特点和预后的研究
发布时间：2018-08-07 06:58
【摘要】：[目的]探讨基于EGFR、KRAS、ALK及EGFR分子亚型非小细胞肺癌患者临床病理特征和预后情况的差异。[方法]回顾性分析2002年7月～2013年2月就诊于中国医学科学院肿瘤医院的1975例非小细胞肺癌患者的临床和病理特征,包括年龄、性别、吸烟状况、家族史、临床分期、肿瘤分期、肿瘤大小、病理类型及分化程度并通过电话随访获得患者生存资料。分析基于不同分子病理分型非小细胞肺癌患者临床病理特征和预后情况差异。[结果]EGFR阳性突变尤其经典突变肿瘤生物学行为良好,中位生存期为61.6月；KRAS突变阳性高发于50岁以上吸烟男性患者,中位生存期为26.0月；ALK融合基因阳性高发于年轻不吸烟女性,具有更强的转移能力,中位生存期为32.3月。吉非替尼、厄洛替尼、埃克替尼具有类似的临床疗效,同化疗相比均不改善EGFR阳性非小细胞肺癌患者的总生存期。[结论]EGFR、KRAS、ALK阳性非小细胞肺癌患者具有不同的临床病理特点和预后情况。行EGFR、KRAS、ALK病理检测分析对判断非小细胞肺癌患者临床病理特征和预后具有临床指导意义。
[Abstract]:[objective] to investigate the differences in clinicopathological features and prognosis of patients with non-small cell lung cancer (NSCLC) based on EGFR KRASA ALK and EGFR molecular subtypes. [methods] the clinical and pathological features of 1975 patients with non-small cell lung cancer (NSCLC) from July 2002 to February 2013 were analyzed retrospectively, including age, sex, smoking status, family history and clinical stage. Tumor staging, tumor size, pathological type and differentiation were obtained by telephone follow-up. To analyze the difference of clinicopathological features and prognosis of non-small cell lung cancer patients based on different molecular pathological classification. [results] the biological behavior of EGFR positive mutation, especially classical mutation, was good. The median survival time was 61.6 months and the median survival time was 26.0 months in smoking men over 50 years old. The positive rate of ALK fusion gene was high in young non-smoking women and had stronger metastatic ability. The median survival time was 32. 3 months. Gefitinib, erlotinib, and ectini have similar clinical efficacy and do not improve the overall survival time of patients with EGFR positive NSCLC compared with chemotherapy. [conclusion] EGFR KRASALK positive NSCLC patients have different clinicopathological features and prognosis. The pathological examination and analysis of EGFR KRASL ALK are of clinical significance in judging the clinicopathological characteristics and prognosis of NSCLC patients.
【学位授予单位】：北京协和医学院
【学位级别】：博士
【学位授予年份】：2015
【分类号】：R734.2
，
本文编号：2169234
[Abstract]:[objective] to investigate the differences in clinicopathological features and prognosis of patients with non-small cell lung cancer (NSCLC) based on EGFR KRASA ALK and EGFR molecular subtypes. [methods] the clinical and pathological features of 1975 patients with non-small cell lung cancer (NSCLC) from July 2002 to February 2013 were analyzed retrospectively, including age, sex, smoking status, family history and clinical stage. Tumor staging, tumor size, pathological type and differentiation were obtained by telephone follow-up. To analyze the difference of clinicopathological features and prognosis of non-small cell lung cancer patients based on different molecular pathological classification. [results] the biological behavior of EGFR positive mutation, especially classical mutation, was good. The median survival time was 61.6 months and the median survival time was 26.0 months in smoking men over 50 years old. The positive rate of ALK fusion gene was high in young non-smoking women and had stronger metastatic ability. The median survival time was 32. 3 months. Gefitinib, erlotinib, and ectini have similar clinical efficacy and do not improve the overall survival time of patients with EGFR positive NSCLC compared with chemotherapy. [conclusion] EGFR KRASALK positive NSCLC patients have different clinicopathological features and prognosis. The pathological examination and analysis of EGFR KRASL ALK are of clinical significance in judging the clinicopathological characteristics and prognosis of NSCLC patients.
【学位授予单位】：北京协和医学院
【学位级别】：博士
【学位授予年份】：2015
【分类号】：R734.2
，
本文编号：2169234
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2169234.html
